420 related articles for article (PubMed ID: 31481273)
1. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
Lin CH; Chen FC; Chan HY; Hsu CC
Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
[TBL] [Abstract][Full Text] [Related]
2. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
Lin CH; Chan HY; Hsu CC; Chen FC
J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
[TBL] [Abstract][Full Text] [Related]
3. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
Lin CH; Chen FC; Chan HY; Hsu CC
Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
5. Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics.
Lin CH; Chan HY; Wang FC; Hsu CC
Ther Adv Psychopharmacol; 2022; 12():20451253221079165. PubMed ID: 35340566
[TBL] [Abstract][Full Text] [Related]
6. Schizophrenia Patients Discharged on Clozapine Plus Long-Acting Injectable Antipsychotics From a Public Psychiatric Hospital in Taiwan, 2006-2021.
Lin TC; Lin CH
Int J Neuropsychopharmacol; 2023 Nov; 26(11):808-816. PubMed ID: 37616565
[TBL] [Abstract][Full Text] [Related]
7. Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics.
MacEwan JP; Kamat SA; Duffy RA; Seabury S; Chou JW; Legacy SN; Hartry A; Eramo A; Karson C
Psychiatr Serv; 2016 Nov; 67(11):1183-1188. PubMed ID: 27417897
[TBL] [Abstract][Full Text] [Related]
8. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
Kishimoto T; Robenzadeh A; Leucht C; Leucht S; Watanabe K; Mimura M; Borenstein M; Kane JM; Correll CU
Schizophr Bull; 2014 Jan; 40(1):192-213. PubMed ID: 23256986
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
[TBL] [Abstract][Full Text] [Related]
10. Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients With Treatment-Resistant Schizophrenia Receiving Clozapine: A Retrospective Cohort Study.
Tien Y; Wang XY; Huang SC; Huang HP
J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38696112
[No Abstract] [Full Text] [Related]
11. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
Huang CY; Fang SC; Shao YJ
JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.
Kishimoto T; Hagi K; Nitta M; Leucht S; Olfson M; Kane JM; Correll CU
Schizophr Bull; 2018 Apr; 44(3):603-619. PubMed ID: 29868849
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.
Misawa F; Kishimoto T; Hagi K; Kane JM; Correll CU
Schizophr Res; 2016 Oct; 176(2-3):220-230. PubMed ID: 27499361
[TBL] [Abstract][Full Text] [Related]
14. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study.
Verdoux H; Pambrun E; Tournier M; Bezin J; Pariente A
Acta Psychiatr Scand; 2017 May; 135(5):429-438. PubMed ID: 28332704
[TBL] [Abstract][Full Text] [Related]
15. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
[TBL] [Abstract][Full Text] [Related]
16. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
Fang SC; Huang CY; Shao YJ
J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35649156
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of long-acting injectable
Vita G; Tavella A; Ostuzzi G; Tedeschi F; De Prisco M; Segarra R; Solmi M; Barbui C; Correll CU
Ther Adv Psychopharmacol; 2024; 14():20451253241257062. PubMed ID: 38831918
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
19. In-Hospital Use of Long-Acting Injectable Antipsychotics and Readmission Risk in Patients With First-Admission Schizophrenia in Taiwan.
Chen W; Wu CS; Liu CC; Kuo PH; Chan HY; Lin YH; Chung YE; Chen WJ
JAMA Netw Open; 2024 Jun; 7(6):e2417006. PubMed ID: 38884998
[TBL] [Abstract][Full Text] [Related]
20. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.
Peters L; Krogmann A; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
Curr Psychiatry Rep; 2019 Nov; 21(12):124. PubMed ID: 31745659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
